Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB1 | Q9H4B7 | 4/20 | 0.59 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.59 |
| ▸ | TUBB | P07437 | 2/20 | 0.59 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.59 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.59 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.59 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.59 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.59 |
| ▸ | TUBB2A | Q13885 | 2/20 | 0.59 |
| ▸ | TUBB8 | Q3ZCM7 | 2/20 | 0.59 |
| ▸ | TUBA3E | Q6PEY2 | 2/20 | 0.59 |
| ▸ | TUBA1A | Q71U36 | 2/20 | 0.59 |
| ▸ | TUBA1C | Q9BQE3 | 2/20 | 0.59 |
| ▸ | TUBB6 | Q9BUF5 | 2/20 | 0.59 |
| ▸ | TUBB2B | Q9BVA1 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.51 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9243553 | 0.83 | TUBB1 (0.56) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL5069897 | 0.80 | TUBB1 (0.57) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL5181745 | 0.79 | NQO2 (0.54) | MEN1KMT2AABCB1NQO2ALDH1A1 | |
| SCHEMBL11796150 | 0.74 | ABCB1 (0.83) | ABCB1TNFRSF1AALDH1A1CYP1A2ABCG2 | |
| SCHEMBL11796142 | 0.74 | ABCB1 (0.83) | ABCB1TNFRSF1AALDH1A1CYP1A2ABCG2 | |
| SCHEMBL9184995 | 0.74 | TUBB1 (1.00) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL5071969 | 0.74 | ALDH1A1 (0.57) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL919833 | 0.74 | TUBB1 (1.00) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL4416013 | 0.74 | TUBB1 (1.00) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL14198035 | 0.74 | GAA (0.56) | TUBB1TUBB4ATUBBTUBA3CTUBA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230255989-A1 | GLYCAN COMPOSITIONS AND USES THEREOF | DSM NUTRITIONAL PRODUCTS LLC (US) | 2023-08-17 | — | — | US | disclosed |
| US-11229660-B2 | Glycan therapeutics and method of treating conditions associated with TMAO | KALEIDO BIOSCIENCES, INC. (US) | 2022-01-25 | — | — | US | disclosed |
| US-20210137956-A1 | GLYCAN COMPOSITIONS AND USES THEREOF | HERCULES CAPITAL, INC. | 2021-05-13 | — | — | US | disclosed |
| US-20210113596-A1 | GLYCAN THERAPEUTICS AND RELATED METHODS THEREOF | KALEIDO BIOSCIENCES, INC. (US) | 2021-04-22 | — | — | US | disclosed |
| US-10881676-B2 | Glycan therapeutics and related methods thereof | KALEIDO BIOSCIENCES, INC. (US) | 2021-01-05 | — | — | US | disclosed |
| US-10702542-B2 | Glycan therapeutics and related methods thereof | KALEIDO BIOSCIENCES, INC. (US) | 2020-07-07 | — | — | US | disclosed |
| US-20200093851-A1 | GLYCAN THERAPEUTICS AND RELATED METHODS THEREOF | HERCULES CAPITAL, INC. | 2020-03-26 | — | — | US | disclosed |
| US-20200093845-A1 | GLYCAN THERAPEUTICS AND RELATED METHODS THEREOF | HERCULES CAPITAL, INC. | 2020-03-26 | — | — | US | disclosed |
| US-10314853-B2 | Glycan therapeutics and related methods thereof | KALEIDO BIOSCIENCES, INC. (US) | 2019-06-11 | — | — | US | disclosed |
| US-20180235987-A1 | GLYCAN COMPOSITIONS AND USES THEREOF | HERCULES CAPITAL, INC. | 2018-08-23 | — | — | US | disclosed |
| US-20180147222-A1 | GLYCAN THERAPEUTICS AND RELATED METHODS THEREOF | HERCULES CAPITAL, INC. | 2018-05-31 | — | — | US | disclosed |
| US-9901595-B2 | Glycan therapeutics for reducing blood ammonia | KALEIDO BIOSCIENCES, INC. (US) | 2018-02-27 | — | — | US | disclosed |
| US-9757403-B2 | Glycan therapeutics and related methods thereof | KALEIDO BIOSCIENCES, INC. (US) | 2017-09-12 | — | — | US | disclosed |
| US-20170246201-A1 | GLYCAN THERAPEUTICS AND RELATED METHODS THEREOF | HERCULES CAPITAL, INC. | 2017-08-31 | — | — | US | disclosed |
| US-20170151269-A1 | GLYCAN THERAPEUTICS AND RELATED METHODS THEREOF | HERCULES CAPITAL, INC. | 2017-06-01 | — | — | US | disclosed |
| US-20170151268-A1 | GLYCAN THERAPEUTICS AND RELATED METHODS THEREOF | HERCULES CAPITAL, INC. | 2017-06-01 | — | — | US | disclosed |
| US-9492473-B2 | Glycan therapeutics and related methods thereof | KALEIDO BIOSCIENCES, INC. (US) | 2016-11-15 | — | — | US | disclosed |
| US-20160213702-A1 | GLYCAN THERAPEUTICS AND RELATED METHODS THEREOF | KALEIDO BIOSCIENCES, INC. (US) | 2016-07-28 | — | — | US | disclosed |